This discussion- and case-based webcast aims to raise awareness of chronic kidney disease (CKD) as a silent component in multi-morbid patients and provide evidence-based strategies and tools for early identification and management of CKD in primary care. This webcast is suitable for Primary Care Practitioners (PCPs) worldwide who provide front-line care of patients with CKD.
Available in English, Français, Español, Deutsch, Português and Italiano.
Please take a moment to complete the feedback form after viewing.
Full webcast
Chapter 1: Introduction and burden of CKD in primary care
Chapter 2: Identification and stratification of CKD in primary care: a patient journey
Chapter 3: Management of CKD in primary care: a patient journey
Chapter 4: How can primary care be supported to bridge the CKD gap? Live discussion and audience Q&A
Accreditation and evaluation
Chronic kidney disease (CKD) affects approximately 850 million people worldwide, however it is often referred to as a ‘silent disease’, as symptoms do not usually appear until the advanced stage, meaning that it is underrecognized by patients and clinicians.
As primary care is often the first point of contact for patients with CKD, the burden commonly falls on primary care physicians (PCPs) to identify and initially manage these patients. It is therefore crucial that PCPs are aware of CKD as a silent component in the primary care setting, so they can be proactive with screening and initiate appropriate strategies for diagnosis and management.
Clinical experts
Samuel Seidu (UK)
Co-chair
Professor of primary care diabetes and cardio-metabolic medicine, Diabetes Research Centre University of Leicester, UK
Baruch Itzhak (Israel)
Co-chair
Diabetologist Specialist in Family Medicine, Clalit Health Services, Technion faculty of medicine, Israel
Louise Moist (Canada)
Expert participant
Professor of Medicine and Epidemiology, London Health Sciences Centre, Canada
Agenda
Time | Session | Speaker |
---|---|---|
5 min | Welcome and introduction | Samuel Seidu |
10 min | Burden of CKD in primary care | Samuel Seidu |
20 min | Identification and stratification of CKD in primary care: a patient journey Case-based discussion | All |
20 min | Management of CKD in primary care: a patient journey Case-based discussion | All |
15 min | How can primary care be supported to bridge the CKD gap? Live discussion and audience Q&A | All |
5 min | Summary and close | Baruch Itzhak |
Learning Objectives
Following completion of this independent educational program, you will be able to:
WONCA Europe endorses and supports the live webinar and on-demand webcast “CKD in primary care: early identification and intervention for improved outcomes”.
PCDE endorses and supports the live webinar and on-demand webcast “CKD in primary care: early identification and intervention for improved outcomes”.
AstraZeneca has provided a sponsorship grant towards this independent program.
Dr Sam Seidu is a Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK. He is currently the vice-chair for Research for Primary Care Diabetes Europe (PCDE).
He is a board member of the Primary Care Diabetes Society of UK and is also currently a Clinical Lead and mentor for diabetes in the Leicester, Leicestershire, and Rutland Integrated Care System. In 2021, he was named the most outstanding early career researcher by the Royal College of General Practitioners. He is a practicing Leicester City General Practitioner, and Partner, lead undergraduate tutor and GP trainer at the Hockley Farm Medical Practice. He is an associate editor of the Primary Care Diabetes journal.
His research aims include medication safety in diabetes and cardiometabolic diseases in the elderly population, quality improvement in diabetes care in primary care settings, and addressing health inequalities in diabetes care. He is also working in the area on therapeutic inertia in people with diabetes to understand the causes, outcomes, and possible solutions.
Disclosures
Receipt of grants/research supports
Janssen, Sanofi, AstraZeneca
Receipt of honoraria or consultation fees
Boehringer Ingelheim, Lilly, MSD, Novartis, Novo Nordisk and Janssen, Amgen, Sanofi, AstraZeneca and Abbott
Participation in a company sponsored speaker’s bureau
Boehringer Ingelheim, Lilly, MSD, Novartis, Novo Nordisk and Janssen, Amgen, Sanofi, AstraZeneca and Abbott
Dr. Baruch Itzhak works as a clinician and diabetologist in primary care settings at Clalit Health Services in Israel. He is recognized as a teacher for medical students and residents in Family Medicine and Diabetes, and the project coordinator of Diabetes Education and Quality Assurance in the Community.
He is a member of EASD, Israel Association of Family Physicians, Israel National Diabetes council and a board member of the Israel Diabetes Association. He is involved in national and international projects for Diabetes Prevention. Dr. Itzhak is a clinical investigator of Diabetes, Lipids and Hypertension in the Research Unit, Lin Medical Center, Haifa, where he is involved in many clinical studies Phase 2b and Phase 3.
His special interest is the prevention of Diabetes and related complications, and early initiation and intensification of injectable therapies among primary care providers. He has published many articles related to Diabetes and complications in primary care. He is an active speaker in national and international conferences and has participated in many advisory panels.
He is the current secretary of the Diabetes & Cardiovascular disease (D & CVD) Study Group related to EASD and a council member of EPCCS. He is a member of PCDE steering committee and an active member of WONCA Europe.
Disclosures
Receipt of honoraria or consultation fees
AstraZeneca, Bayer, Novo Nordisk, Boerhinger Ingelheim, Eli Lilly, Sanofi, Roche, Abbott, MSD
Dr. Moist is a Clinician Researcher and Professor of Medicine, Epidemiology and Biostatistics at the University of Western Ontario, Associate Chair, Division of Nephrology and Associate Director of the Center for Quality Improvement and Patient Safety.
Dr Moist is a Certified Canadian Physician Executive, credentialing her significant role in healthcare leadership. Dr Moist is an active clinician, teacher and researcher. Her research focus is in vascular access, CKD progression and quality improvement.
Dr Moist’s publications include over 200 peer reviewed papers and her recent research is in Implementation Science, integrating best evidence to best practice. Recent awards include the Canadian Society of Nephrology Distinguished Service Award (2020) , MAC Chairs Award for outstanding contribution to quality improvement and patient safety (2018).
Disclosures
Receipt of honoraria or consultation fees
Otsuka, AstraZeneca, Boerhinger Ingelheim, Eli Lilly, Novo Nordisk, Janssen
Prof. Ungan is the immediate past President of the WONCA Europe, and past President of the European General Practice Research Network (EGPRN). He is an active Professor at Ankara University School of Medicine, Department of Family Medicine.
He graduated from Istanbul University (1987). Completed Postgraduate specialization on Family Medicine in 1993. Is a founder and former President of the Turkish Association of Family Physicians, and a member of the Academic Board. He was certified as GP Trainer in University of Exeter Postgraduate Medical School, UK in 1993, worked as Deputy Medical Director of the METU University for 18 years, and was an advisor of the Ministry on FM/GP.
Prof. Ungan is in the editorial boards of many PC journals, and organized WONCA Europe and its network Conferences in Türkiye in 2003, 2008, and 2015. His practice is in Ankara, Trained in Global TB Institute, Newark- NY. Currently, he is a board member of IPPA and an expert in WHO Europe on Primary care. His researches are in the field of Primary Care, Family Practice, screening, and migrant health. In addition to books and book chapters of more than 100 printed articles cited, he has a preferred place in the professor assignment in international juries of academic positions in foreign universities as well as national inter-universities commission duties.
Disclosures
None to declare